Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. - Wikidata - awgldk - TriplyDB

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.

http://www.wikidata.org/entity/Q44917836

about

Mepolizumab versus placebo for asthma Omalizumab for asthma in adults and children Anti-IgE for chronic asthma in adults and children Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease Biomarkers and severe asthma: a critical appraisal Emerging role of mast cells and macrophages in cardiovascular and metabolic diseases Severe asthma: anti-IgE or anti-IL-5?Management of the patient with eosinophilic asthma: a new era begins Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential Biologics in asthma--the next step toward personalized treatment Monoclonal antibodies and other biologic agents in the treatment of asthma Targeting patients with asthma for omalizumab therapy: choosing the right patient to get the best value for money.The role of allergy in severe asthma.Asthma outcomes: pulmonary physiology.Asthma outcomes: biomarkers IgE alone promotes human lung mast cell survival through the autocrine production of IL-6.Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.The role of omalizumab in the treatment of severe allergic asthma.Asthma linked with rhinosinusitis: An extensive review.Syk expression in peripheral blood leukocytes, CD34+ progenitors, and CD34-derived basophils.Regulation of human mast cell and basophil function by anaphylatoxins C3a and C5a.Regulation of Syk kinase and FcRbeta expression in human basophils during treatment with omalizumab.Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy.Anti-IgE therapy results in decreased myeloid dendritic cells in asthmatic airways.Mechanisms Mediating Pediatric Severe Asthma and Potential Novel Therapies.Regulation of Fc∈RI signaling in mast cells by G protein-coupled receptor kinase 2 and its RH domain.Omalizumab in the treatment of asthma.Airway remodelling in asthma: from benchside to clinical practice.Difficult-to-control asthma management through the use of a specific protocol Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients.Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.Omalizumab in children.Mast cells can promote the development of multiple features of chronic asthma in mice.Omalizumab in the management of patients with allergic (IgE-mediated) asthma.New therapies and management strategies in the treatment of asthma: patient-focused developments.Update on optimal use of omalizumab in management of asthma.Optimal management of severe/refractory asthma.A pilot study of omalizumab in eosinophilic esophagitis How has research in the last five years changed my clinical practice?Type 2 inflammation in asthma--present in most, absent in many

P2860

Q24186306-A8BA5551-A2EA-429F-ABD7-C1A5F5238390 Q24201145-FFD16697-3E38-45ED-A574-36991A788986 Q24246484-9EA8B38A-1DAA-4DCC-A51E-2E4E6A0C5E73 Q26771819-BF66CF98-9E96-42BB-A4E0-EBE71EAA5166 Q26782718-287BDC71-87E4-47B6-866C-C668E374F904 Q26825467-1FA53FF5-E2B3-49B6-9776-858F0CDF0A88 Q28071832-BE9851AD-0C6A-4AB8-B975-61B86C20AFBF Q28078191-593D0D77-4CAF-4539-B94A-8BA3CDA8C8D0 Q28080207-FB1951A1-A7EF-4E6D-9152-15ADB799D29E Q28085614-77331F83-3676-45C6-BC4F-0C65A353EBDC Q28270037-30885FCB-40B5-43F7-939B-6900BD892B3A Q30360362-A14FEA5F-467C-481C-84F2-FC6F96400816 Q30419500-1D4586CE-910A-44CD-8BAD-7B99662471F6 Q30423167-2CACB128-9D48-42DC-8C7A-5CF4EFAA1B07 Q30425168-59AB7237-4B0E-433A-A067-8F8D753E247F Q33316194-2D943C47-BEAF-4C81-A8C6-A359FA88C756 Q33588223-EAD5C024-3E36-42F6-BC71-B8A31E740722 Q33591890-04D6A677-9759-4D59-B482-4DB66590AB82 Q33605489-F9E105ED-50A8-46C6-8097-22713F320B36 Q33615243-EE91A58B-738B-4223-9519-526D23EE9669 Q33625259-DE8C3639-F365-4B2C-B22F-C5646CAC87E0 Q33774660-850AA6FC-9FCE-4DEB-B422-48FA1A768E49 Q33785112-4AF2357C-A883-4C2F-BFEA-DAC112E972F6 Q33838444-0965DBA0-81B4-4566-8796-B9A6AC6A66D0 Q33871749-38AAE89A-2255-414C-88A6-B2C4925976AA Q33947182-DE8824A8-89DE-404A-A02B-1EC7EB8C4C23 Q34029374-26FE365A-CC31-4933-89CB-F15C349AE6DB Q34105688-CD692580-3D4B-401A-9BC2-73556BA9936C Q34197997-F633C7E3-4B7F-4196-B35F-CFA2BEBC4F5F Q34303895-D11DDD1A-A5D0-40E3-A0F4-20CCB8CFF768 Q34412092-32577421-FA2B-4677-859D-12DCC551746E Q34604574-E14CCC3A-8F95-46C0-A729-440C074ED207 Q34619598-C8D49541-9D53-44BB-B5C6-0C90CD9A334B Q34623856-9585CA88-1DB8-40B9-92E4-56BE85A27FC7 Q35025262-A8BD265B-74A4-44E0-A4A8-2A7A5C98C9A6 Q35117827-123BEA38-B4F4-42AD-9EDD-E408C0BDEDA9 Q35193179-D88332AA-CA93-4499-9685-CA0609BF3873 Q35195626-43E1A0AC-14F8-4B95-AFD4-99475A5A168F Q35284521-F521A786-9730-4CC9-8216-ACFCDC259F0A Q35322784-BBA4D499-5F91-4551-90A2-DA05FD8E3FFA

P2860

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.

http://www.wikidata.org/entity/Q44917836

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Effects of treatment with anti ...... flammation in allergic asthma.

@en

Effects of treatment with anti ...... flammation in allergic asthma.

@nl

type

label

Effects of treatment with anti ...... flammation in allergic asthma.

@en

Effects of treatment with anti ...... flammation in allergic asthma.

@nl

prefLabel

Effects of treatment with anti ...... flammation in allergic asthma.

@en

Effects of treatment with anti ...... flammation in allergic asthma.

@nl

P1433

Q44917836-3C50F87E-F182-4873-BA6D-675936FB5B1E

P1476

Q44917836-CAB8D570-6FF8-4A8F-8135-B4212DE52678

P2093

Q44917836-152CA926-53CF-4345-8FED-DB130B754BB0

Q44917836-197D677D-D5B6-4EBC-B762-7D18BA9525D3

Q44917836-26F8CF03-F8DC-46A2-AE83-D652FA161C16

Q44917836-3308D0A0-A2DB-4159-9722-1D55532B993B

Q44917836-376EFB85-48C5-4C09-843A-D5249EBF9E50

Q44917836-6C62AB90-A796-4EFD-928E-511D2D6C89E3

Q44917836-B9FD8F20-67D6-4F29-8EE8-A553B652F083

Q44917836-EDAB31C7-F169-458F-89D6-0849DFD9C4A1

P2860

Q44917836-02FCDC5A-3D5D-46B5-82C0-9320898AE00B

Q44917836-0A70D6C4-CC43-4A49-A57A-57B427B224CF

Q44917836-11BF36FC-A8DC-4169-B095-3B2DD8C156D2

Q44917836-1BB83F34-F997-44D0-98C0-6D31BB4C9E0C

Q44917836-1E24A8C4-AF8D-4828-B693-FAEF970973F5

Q44917836-26A30242-D3DC-4D50-BBDC-93139C9ED6FD

Q44917836-2A2F8320-E595-4432-B3C6-47290896A946

Q44917836-35005160-77DE-47E8-A617-670D6A314EDD

Q44917836-457CCF3B-D5F4-4FBE-9784-3E157B7918A9

Q44917836-49278194-2775-4F03-B2E4-23C1CEC0F6EA

P304

Q44917836-13E7DE7D-666D-416B-BD8C-7C1068DBC43C

P31

Q44917836-5F986056-1F18-48EA-814C-10EEEF6CFD69

P356

Q44917836-57B432EE-9543-448E-89F0-F1F163EC0B91

P407

Q44917836-4DF45759-B471-42F4-8A61-912F8CE33F50

P433

Q44917836-6A4B2EEB-FAD6-4A83-B414-10C789D86C5C

P478

Q44917836-C63A0E34-4429-41D5-947B-BC5012394855

P50

Q44917836-33F997A0-4CD7-4CDA-8CE8-9184C5EA01B7

Q44917836-53094BAB-9F3B-44AB-8EB9-1C5F32866A37

Q44917836-7BA5D4EC-E9BE-4194-A71C-F7612055CD50

Q44917836-D8507C54-BF8B-4BDB-BC70-8F130CAF5FF5

P577

Q44917836-F4D21D0D-CFBB-4024-83D5-A9922F3D3BED

P698

Q44917836-7F322B76-7F9A-42FB-8574-ABC9E8DF521A

P921

Q44917836-0ACDE918-7F8D-45F2-A4F0-361A44BDAA33

Q44917836-544BB93F-9AC9-4F0E-9C24-E922FC4CD0A2

Q44917836-859C5004-219E-4D8A-A343-463DC3D5D465

P356

RCCM.200312-1651OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Effects of treatment with anti ...... flammation in allergic asthma.

@en

P2093

Angel Fowler-Taylor

http://www.w3.org/2001/XMLSchema#string

John Matthews

http://www.w3.org/2001/XMLSchema#string

John V Fahy

http://www.w3.org/2001/XMLSchema#string

Mark Steel

http://www.w3.org/2001/XMLSchema#string

Monica Kraft

http://www.w3.org/2001/XMLSchema#string

Nizar N Jarjour

http://www.w3.org/2001/XMLSchema#string

Susan J Wilson

http://www.w3.org/2001/XMLSchema#string

Weibin Bao

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines

Pathophysiology of the inflammatory response.

Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms.

Low-affinity IgE receptor (CD23) function on mouse B cells: role in IgE-dependent antigen focusing.

The trials and tribulations of IL-5, eosinophils, and allergic asthma.

Distribution and degranulation of airway mast cells in normal and asthmatic subjects.

Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma.

Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma.

Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics.

Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma.

P304

583-593

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.200312-1651OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

170

http://www.w3.org/2001/XMLSchema#string

P50

Stephen T. Holgate

Ratko Djukanovic

William W Busse

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15172898

http://www.w3.org/2001/XMLSchema#string

P921